NCT03210935

Brief Summary

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are :

  • to provide epidemiological, clinical and socio-economic characteristics of patients
  • to identify new clinical or epidemiological prognostic factors for these rare cancers
  • to evaluate the impact of various treatments on outcomes

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
9,000

participants targeted

Target at P75+ for all trials

Timeline
6mo left

Started Nov 2015

Longer than P75 for all trials

Geographic Reach
1 country

34 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Nov 2015Dec 2026

Study Start

First participant enrolled

November 24, 2015

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

July 4, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 7, 2017

Completed
9.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

May 22, 2026

Status Verified

May 1, 2026

Enrollment Period

11.1 years

First QC Date

July 4, 2017

Last Update Submit

May 20, 2026

Conditions

Adnexal Tumor of SkinMerkel Cell CarcinomaAdvanced Basal Cell Carcinoma Requiring Systemic Treatment

Keywords

Adnexal cutaneous carcinomaMerkel cell carcinomaAdvanced basal cell carcinoma requiring systemic treatment

Outcome Measures

Primary Outcomes (1)

  • Incidence and natural history of the 3 types of rare skin cancers

    10 years

Study Arms (3)

Merkel cell carcinoma

Advanced basal cell carcinoma

Cutaneous adnexal carcinomas

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

You may qualify if:

  • Patients with histologically confirmed Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma

You may not qualify if:

  • Subjects without Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, or cutaneous adnexal carcinoma
  • Patients refusal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (34)

CHU Bocage

Dijon, Dijon, 21079, France

RECRUITING

CH Le Mans

Le Mans, Le Mans, 72037, France

RECRUITING

Centre hospitalier Lyon Sud

Pierre-Bénite, Pierre-benite, 69495, France

RECRUITING

CHU Amiens Picardie

Amiens, France

RECRUITING

CHU Angers

Angers, France

RECRUITING

CH Annecy Gennevois

Annecy, France

RECRUITING

CHU Besançon

Besançon, France

RECRUITING

CHU Avicenne

Bobigny, France

RECRUITING

CHU Ambroise Paré

Boulogne-Billancourt, France

RECRUITING

CHU de Brest

Brest, France

RECRUITING

CHU de Caen

Caen, France

RECRUITING

CHU de Clermont Ferrand

Clermont-Ferrand, France

RECRUITING

CHU de Grenoble

Grenoble, France

RECRUITING

CHU de Limoges

Limoges, France

RECRUITING

Centre Léon Bérard

Lyon, France

RECRUITING

Hôpital La Timone

Marseille, France

RECRUITING

Hôpital St Eloi

Montpellier, France

RECRUITING

CHU de Nancy

Nancy, France

RECRUITING

CHU Nantes - Place Alexis Ricordeau

Nantes, France

RECRUITING

CHU de Nice

Nice, France

RECRUITING

CHR d'Orleans

Orléans, France

RECRUITING

CHU Bichat

Paris, France

RECRUITING

CHU Cochin

Paris, France

RECRUITING

CHU St Louis

Paris, France

RECRUITING

CHU de Bordeaux

Pessac, France

RECRUITING

CHU de Pointe à Pitre

Pointe à Pitre, France

RECRUITING

CHU de Poitiers

Poitiers, France

RECRUITING

CHU de Reims

Reims, France

RECRUITING

CHU de Rennes

Rennes, France

RECRUITING

CHU de Rouen

Rouen, France

RECRUITING

CHU de Strasbourg

Strasbourg, France

RECRUITING

CHU de Toulouse - Larrey

Toulouse, France

RECRUITING

CHU de Tours

Tours, France

RECRUITING

Institut Gustave Roussy

Villejuif, France

RECRUITING

Related Links

MeSH Terms

Conditions

Carcinoma, Merkel Cell

Condition Hierarchy (Ancestors)

Polyomavirus InfectionsDNA Virus InfectionsVirus DiseasesInfectionsTumor Virus InfectionsCarcinoma, NeuroendocrineNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Officials

  • Laurent MORTIER, MD,PhD

    University Hospital, Lille

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Laurent MORTIER, MD,PhD

CONTACT

03.20.44.41.93laurent.mortier@chru-lille.fr

Benoit Minart

CONTACT

benoit.minart@chru-lille.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2017

First Posted

July 7, 2017

Study Start

November 24, 2015

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

May 22, 2026

Record last verified: 2026-05

Locations

FR(34)